The first human-tested weight-loss drug that burns calories through creatine-based heat generation, without reducing appetite, has successfully completed its Phase I trial.
Scientists from the Institut Pasteur de Montevideo (IP Montevideo) and the University of the Republic (Udelar) have built on their promising preclinical mouse study to demonstrate that SANA, a small molecule drug that harnesses an unexplored fat-burning pathway, is not only safe for human use but effective.
Related
Posts
An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications.
An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications.
EOLO PHARMA today announced that it has dosed the first subjects in Phase 1 clinical trials of MVD1, designed to prevent and treat obesity and its cardiometabolic complications.
An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications.
Carlos Escande lidera desde 2013 el Laboratorio de Patologías del Metabolismo y el Envejecimiento. Llegó al instituto luego de ser seleccionado con el último llamado internacional para jóvenes líderes que tenía un fondo por cinco años con el objetivo de entender los mecanismos de evolución de las patologías del metabolismo como obesidad, diabetes y enfermedades cardiovasculares.
EOLO PHARMA today announced that it has dosed the first subjects in Phase 1 clinical trials of MVD1, designed to prevent and treat obesity and its cardiometabolic complications.
Eolo Pharma is a company dedicated to improving the health and well-being of individuals. Our high-quality products are designed to enhance energy and vitality, providing innovative solutions for healthcare.
Copyright © 2024 EoloPharma. All rights reserved.
